Drugs / INS1202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07290062 | Jan 2026 → Mar 2030 expected | amyotrophic lateral sclerosis | Insmed Gene Therapy LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INS1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07290062 ↗ |
| Route | Intrathecal | “via IT administration” NCT07290062 ↗ |